| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 7, 2004
Accepted on March 18, 2005
From the Medizinische Klinik (S.F.-M., S.E., W.B., R.D.), Interdisziplinäres Stoffwechsel-Centrum (T.R., U.P.), Endokrinologie, Diabetes, und Stoffwechsel der Medizinischen Klinik, Medizinische Klinik mit Schwerpunkt Nephrologie und Intensivmedizin (P.H.), Universitätsmedizin Charité-Campus Virchow, Humboldt-Universität zu Berlin, and Medizinische Klinik III (M.G.), Universitätsklinikum Tübingen, Germany.
* To whom correspondence should be addressed. E-mail: meinrad.gawaz{at}med.uni-tuebingen.de.
Background--Platelets play a key role in atherogenesis and thromboembolic complications in patients with type 2 diabetes.
Methods and Results--We prospectively examined the relationship between systemic platelet activation and progression of carotid wall thickness within 1 year in 105 patients with type 2 diabetes. The intima-media thickness (IMT) of the common carotid artery was measured bilaterally at study entry and after 1 year. Platelet activation was assessed with the use of immunologic markers of platelet activation (CD62P, CD63, and CD40L) and flow cytometry. The prevalence for progression of atherosclerotic carotid disease in this population was 55.2%. We found that platelet degranulation (CD63 and CD40L) correlated with progression of IMT within 1 year (CD63: r=0.231, P=0.022; CD40L: r=0.230, P=0.029). Diabetic patients with progression of IMT had a significantly increased expression of CD63 compared with patients with stable carotid disease (mean intensity of immunofluorescence; median, interquartile range: 17.1 [12.4, 25.8] versus 11.9 [7.7, 19.8]; P=0.004). Multivariate logistic regression analysis revealed that degranulation of platelet CD63 is a predictor for progression of IMT independently of classical cardiovascular risk factors and hemoglobin A1c in diabetic patients (P=0.017).
Conclusions--Enhanced systemic platelet degranulation is associated with progression of carotid artery disease in type 2 diabetes.
This article has been cited by other articles:
![]() |
D. Liu, A. Maier, A. Scholze, U. Rauch, U. Boltzen, Z. Zhao, Z. Zhu, and M. Tepel High Glucose Enhances Transient Receptor Potential Channel Canonical Type 6-Dependent Calcium Influx in Human Platelets via Phosphatidylinositol 3-Kinase-Dependent Pathway Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 746 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF] |
||||
![]() |
A. Schafer, U. Flierl, A. Kobsar, M. Eigenthaler, G. Ertl, and J. Bauersachs Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2813 - 2818. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yokoyama, N. Katakami, and Y. Yamasaki Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus Stroke, September 1, 2006; 37(9): 2420 - 2427. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Htun, S. Fateh-Moghadam, B. Tomandl, R. Handschu, K. Klinger, K. Stellos, C. Garlichs, W. Daniel, and M. Gawaz Course of Platelet Activation and Platelet-Leukocyte Interaction in Cerebrovascular Ischemia Stroke, September 1, 2006; 37(9): 2283 - 2287. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |